|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang Y, Hochster H, Stein S and Lacy J:
Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer
after first-line FOLFIRINOX: Single institution retrospective
review of efficacy and toxicity. Exp Hematol Oncol. 4:292015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sharma P and Allison JP: The future of
immune checkpoint therapy. Science. 348:56–61. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zheng L, Xue J, Jaffee EM and Habtezion A:
Role of immune cells and immune-based therapies in pancreatitis and
pancreatic ductal adenocarcinoma. Gastroenterology. 144:1230–1240.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
He H and Baldwin GS: p21-activated kinases
and gastrointestinal cancer. Biochim Biophys Acta. 1833:33–39.
2013. View Article : Google Scholar
|
|
7
|
Yeo D, He H, Patel O, Lowy AM, Baldwin GS
and Nikfarjam M: FRAX597, a PAK1 inhibitor, synergistically reduces
pancreatic cancer growth when combined with gemcitabine. BMC
Cancer. 16:242016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tyagi N, Bhardwaj A, Singh AP, McClellan
S, Carter JE and Singh S: p-21 activated kinase 4 promotes
proliferation and survival of pancreatic cancer cells through AKT-
and ERK-dependent activation of NF-κB pathway. Oncotarget.
5:8778–8789. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tyagi N, Marimuthu S, Bhardwaj A, Deshmukh
SK, Srivastava SK, Singh AP, McClellan S, Carter JE and Singh S:
p-21 activated kinase 4 (PAK4) maintains stem cell-like phenotypes
in pancreatic cancer cells through activation of STAT3 signaling.
Cancer Lett. 370:260–267. 2016. View Article : Google Scholar
|
|
10
|
Moon SU, Kim JW, Sung JH, Kang MH, Kim SH,
Chang H, Lee JO, Kim YJ, Lee KW, Kim JH, et al: p21-activated
kinase 4 (PAK4) as a predictive marker of gemcitabine sensitivity
in pancreatic cancer cell lines. Cancer Res Treat. 47:501–508.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Biankin AV, Waddell N, Kassahn KS, Gingras
MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J,
et al Australian Pancreatic Cancer Genome Initiative: Pancreatic
cancer genomes reveal aberrations in axon guidance pathway genes.
Nature. 491:399–405. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Murray BW, Guo C, Piraino J, Westwick JK,
Zhang C, Lamerdin J, Dagostino E, Knighton D, Loi CM, Zager M, et
al: Small-molecule p21-activated kinase inhibitor PF-3758309 is a
potent inhibitor of oncogenic signaling and tumor growth. Proc Natl
Acad Sci USA. 107:9446–9451. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huynh N, Liu KH, Baldwin GS and He H:
p21-activated kinase 1 stimulates colon cancer cell growth and
migration/invasion via ERK- and AKT-dependent pathways. Biochim
Biophys Acta. 1803:1106–1113. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yeo D, Huynh N, Beutler JA, Christophi C,
Shulkes A, Baldwin GS, Nikfarjam M and He H: Glaucarubinone and
gemcitabine synergistically reduce pancreatic cancer growth via
down-regulation of P21-activated kinases. Cancer Lett. 346:264–272.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bang D, Wilson W, Ryan M, Yeh JJ and
Baldwin AS: GSK-3α promotes oncogenic KRAS function in pancreatic
cancer via TAK1-TAB stabilization and regulation of noncanonical
NF-κB. Cancer Discov. 3:690–703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nikfarjam M, Yeo D, He H, Baldwin G, Fifis
T, Costa P, Tan B, Yang E, Wen Sw and Christophi C: Comparison of
two syngeneic orthotopic murine models of pancreatic
adenocarcinoma. J Invest Surg. 26:352–359. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Newman AM and Alizadeh AA: High-throughput
genomic profiling of tumor-infiltrating leukocytes. Curr Opin
Immunol. 41:77–84. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Junttila MR and de Sauvage FJ: Influence
of tumour microenvironment heterogeneity on therapeutic response.
Nature. 501:346–354. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rooney MS, Shukla SA, Wu CJ, Getz G and
Hacohen N: Molecular and genetic properties of tumors associated
with local immune cytolytic activity. Cell. 160:48–61. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Peske JD, Woods AB and Engelhard VH:
Control of CD8 T-cell infiltration into tumors by vasculature and
microenvironment. Adv Cancer Res. 128:263–307. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rusakiewicz S, Semeraro M, Sarabi M,
Desbois M, Locher C, Mendez R, Vimond N, Concha A, Garrido F,
Isambert N, et al: Immune infiltrates are prognostic factors in
localized gastrointestinal stromal tumors. Cancer Res.
73:3499–3510. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sideras K, Braat H, Kwekkeboom J, van
Eijck CH, Peppelenbosch MP, Sleijfer S and Bruno M: Role of the
immune system in pancreatic cancer progression and immune
modulating treatment strategies. Cancer Treat Rev. 40:513–522.
2014. View Article : Google Scholar
|
|
24
|
Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki
M, Kosuge T, Kanai Y and Hiraoka N: Immune cell infiltration as an
indicator of the immune microenvironment of pancreatic cancer. Br J
Cancer. 108:914–923. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fukunaga A, Miyamoto M, Cho Y, Murakami S,
Kawaradaz Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M, Nakakubo Y,
et al: CD8+ tumor-infiltrating lymphocytes together with
CD4+ tumor-infiltrating lymphocytes and dendritic cells
improve the prognosis of patients with pancreatic adenocarcinoma.
Pancreas. 28:e26–e31. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hingorani SR, Wang L, Multani AS, Combs C,
Deramaudt TB, Hruban RH, Rustgi AK, Chang S and Tuveson DA:
Trp53R172H and KrasG12D cooperate to promote chromosomal
instability and widely metastatic pancreatic ductal adenocarcinoma
in mice. Cancer Cell. 7:469–483. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Eriksson E, Wenthe J, Irenaeus S, Loskog A
and Ullenhag G: Gemcitabine reduces MDSCs, tregs and TGFβ-1 while
restoring the teff/treg ratio in patients with pancreatic cancer. J
Transl Med. 14:2822016. View Article : Google Scholar
|
|
28
|
Shibuya KC, Goel VK, Xiong W, Sham JG,
Pollack SM, Leahy AM, Whiting SH, Yeh MM, Yee C, Riddell SR, et al:
Pancreatic ductal adenocarcinoma contains an effector and
regulatory immune cell infiltrate that is altered by multimodal
neoadjuvant treatment. PLoS One. 9:e965652014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Manji GA, Olive KP, Saenger YM and
Oberstein P: Current and emerging therapies in metastatic
pancreatic cancer. Clin Cancer Res. 23:1670–1678. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Philip PA, Benedetti J, Corless CL, Wong
R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC,
Rivkin SE, et al: Phase III study comparing gemcitabine plus
cetuximab versus gemcitabine in patients with advanced pancreatic
adenocarcinoma: Southwest Oncology Group-directed intergroup trial
S0205. J Clin Oncol. 28:3605–3610. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kindler HL, Niedzwiecki D, Hollis D,
Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF,
O'Reilly E, Wozniak TF, et al: Gemcitabine plus bevacizumab
compared with gemcitabine plus placebo in patients with advanced
pancreatic cancer: Phase III trial of the Cancer and Leukemia Group
B (CALGB 80303). J Clin Oncol. 28:3617–3622. 2010. View Article : Google Scholar : PubMed/NCBI
|
